Quick Answer
CNS Pharmaceuticals, Inc. reported Stockholders Equity of $4.52 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $4.52M | -26.8% |
| 2024 | $6.18M | +239.4% |
| 2023 | -$4.43M | -154.5% |
| 2022 | $8.13M | +32.0% |
| 2021 | $6.16M | -55.8% |
| 2020 | $13.95M | +83.5% |
| 2019 | $7.60M | +1483.8% |
| 2018 | -$549.3K | -838.5% |
| 2017 | -$58.5K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.91M | +195.6% | -24.5% |
| June 30, 2025 | $13.12M | +405.7% | +19.6% |
| March 31, 2025 | $10.97M | +347.6% | +77.6% |
| December 31, 2024 | $6.18M | +239.4% | +84.2% |
| September 30, 2024 | $3.35M | +292.6% | +178.1% |
| June 30, 2024 | -$4.29M | -274.9% | +3.1% |
| March 31, 2024 | -$4.43M | -226.9% | +0.0% |
| December 31, 2023 | -$4.43M | -154.5% | -154.6% |
- CNS Pharmaceuticals, Inc. showed a decrease of -26.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, CNS Pharmaceuticals, Inc.’s stockholders equity has grown by 7826.6% (from -$58.5 thousand to $4.52 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: